TT (ATCC® CRL-1803)

Organism: Homo sapiens, human  /  Tissue: thyroid/medulla  /  Disease: Carcinoma

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue thyroid/medulla
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1
Disease Carcinoma
Age 77 years
Gender female
Ethnicity Caucasian
Karyotype aneuploid with several markers; modal number = 40; range = 32 to 86 (. Advances in thyroid neoplasia, 1981. Rome: Field Educational Italia; 1981.)
Derivation
The TT cell line was established by S.S. Leong, et al. from a specimen obtained by needle biopsy from a 77 year old female with thyroid medullary carcinoma.
Clinical Data
77 years
Caucasian
female

Genes Expressed
calcitonin; carcinoembryonic antigen (CEA)
Cellular Products
calcitonin; carcinoembryonic antigen (CEA)
Tumorigenic Yes
Effects
Yes, Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells.
Comments

TT cells continuously produce high levels of calcitonin and CEA.

Immunoreactive calcitonin was found to be produced in cell culture at levels of 3900 pg/million cells and 7700 pg/million cells 24 and 72 hours respectively, after a medium change.

CEA was found to accumulate to greater than 27 ng/million cells over a 72 hours period.

Chromosomal analysis of the cell line and tumors induced in nude mice reveal an aneuploid human karyotype with several marker chromosomes.

The initial characterization studies of the TT cell line were conducted using early passage TT cells cultivated in RPMI 1640 medium supplemented with 15% fetal bovine serum and 1 mM L-glutamine.

It is not known if the neuropeptides reported to be produced by this cell line when it was grown in RPMI 1640 medium are also produced by the cells when they are cultured in Ham's F12K medium.

Chromosomal analysis of the cell line and tumors induced in nude mice reveal an aneuploid human karyotype with several marker chromosomes.



Complete Growth Medium The base medium for this cell line is ATCC-formulated F-12K Medium, Catalog No. 30-2004. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 mL of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37°C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:4 is recommended
Medium Renewal: Twice per week
Cryopreservation
Culture medium, 95%; DMSO, 5%
Culture Conditions
Temperature: 37°C
STR Profile
Amelogenin: X
CSF1PO: 10,13
D13S317: 11
D16S539: 12,13
D5S818: 12,13
D7S820: 10,12
THO1: 6,9
TPOX: 8,11
vWA: 16,18
Population Doubling Time 83 hrs
Name of Depositor SS Leong
Passage History
The initial characterization studies of the TT cell line were conducted using early passage TT cells cultivated in RPMI 1640 medium supplemented with 15% fetal bovine serum and 1 mM L-glutamine.
References

. Advances in thyroid neoplasia, 1981. Rome: Field Educational Italia; 1981.

Behr TM, et al. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res. 57: 5309-5319, 1997. PubMed: 9393755

. Advances in thyroid neoplasia, 1981. Rome: Field Educational Italia; 1981.

Cross References

Nucleotide (GenBank) : AJ275978 Homo sapiens partial mRNA LAGE-2b for hypothetical protein (LAGE-2 gene).

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

. Advances in thyroid neoplasia, 1981. Rome: Field Educational Italia; 1981.

Behr TM, et al. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res. 57: 5309-5319, 1997. PubMed: 9393755

. Advances in thyroid neoplasia, 1981. Rome: Field Educational Italia; 1981.